BB-kb@ldeleger:BB-kb-9521147 / 175-1742 JSONTXT

Annnotations TAB JSON ListView MergeView

bionlp-ost-19-BB-kb-dev

Below, discontinuous spans are shown in the chain model. You can change it to the bag model.

Id Subject Object Predicate Lexical cue NCBI_Taxonomy OntoBiotope
T2 0-1567 Paragraph denotes Different lines of evidence suggest that a discrepancy between the distribution of Burkholderia (Pseudomonas) pseudomallei in the environment and the distribution of the disease melioidosis is attributable, at least in part, to phenotypic differences between clinical and some environmental isolates. Two antigenically and biochemically distinct biotypes have been described, only one of which is virulent. In this study, lipopolysaccharides (LPSs) were extracted by the proteinase K digestion method from a total of 214 B. pseudomallei isolates, and their immunoreactivities with sera from patients with different clinical spectra and with other infections were evaluated. With the exception of4 isolates from a total of 214 tested, the sodium dodecyl sulfate-polyacrylamide gel electrophoresis silver-staining profiles of the LPSs from the two biotypes showed identical ladder patterns that were typical for smooth LPSs from other gram-negative bacteria. The 210 isolates with typical LPS patterns (119 Ara- clinical, 13 Ara- soil, 70 Ara+ soil, and 8 reference National Type Culture Collection strains) also exhibited similar immunoblot profiles against pooled sera from patients with melioidosis and hyperimmune mouse sera. Concordant findings were noted in the indirect enzyme-linked immunosorbent assay with Ara- and Ara+ LPSs to coat the microtiter plates. The LPSs of the different B. pseudomallei biotypes appear antigenically indistinguishable. It is, therefore, unlikely that this component is related to the virulence and pathogenicity of B. pseudomallei.
T8 83-122 Microorganism denotes Burkholderia (Pseudomonas) pseudomallei 28450
T9 259-267 Habitat denotes clinical OBT:003220
T10 397-405 Phenotype denotes virulent OBT:000375
T11 521-536 Microorganism denotes B. pseudomallei 28450
T12 581-657 Habitat denotes sera from patients with different clinical spectra and with other infections OBT:000524
T13 591-657 Habitat denotes patients with different clinical spectra and with other infections OBT:003269
T14 933-946 Phenotype denotes gram-negative OBT:000648
T15 1005-1009 Microorganism denotes Ara- 28450
T16 1010-1018 Habitat denotes clinical OBT:003220
T17 1023-1027 Microorganism denotes Ara- 28450
T18 1028-1032 Habitat denotes soil OBT:000427
T19 1037-1041 Microorganism denotes Ara+ 95163
T20 1042-1046 Habitat denotes soil OBT:000427
T21 1164-1199 Habitat denotes sera from patients with melioidosis OBT:000524
T22 1174-1199 Habitat denotes patients with melioidosis OBT:003269
T24 1204-1226 Habitat denotes hyperimmune mouse sera OBT:000524
T23 1204-1221 Habitat denotes hyperimmune mouse OBT:003211
T25 1314-1318 Microorganism denotes Ara- 28450
T26 1323-1327 Microorganism denotes Ara+ 95163
T27 1345-1362 Habitat denotes microtiter plates OBT:000103
T28 1390-1405 Microorganism denotes B. pseudomallei 28450
T29 1520-1529 Phenotype denotes virulence OBT:000375
T30 1534-1547 Phenotype denotes pathogenicity OBT:000375
T31 1551-1566 Microorganism denotes B. pseudomallei 28450
E4 521-536 Lives_In denotes B. pseudomallei
E5 521-536 Lives_In denotes B. pseudomallei
E6 1005-1009 Lives_In denotes Ara-
E7 1005-1009 Lives_In denotes Ara-
E8 1005-1009 Lives_In denotes Ara-
E9 1005-1009 Lives_In denotes Ara-
E10 1005-1009 Lives_In denotes Ara-
E11 1023-1027 Lives_In denotes Ara-
E12 1023-1027 Lives_In denotes Ara-
E13 1023-1027 Lives_In denotes Ara-
E14 1023-1027 Lives_In denotes Ara-
E15 1023-1027 Lives_In denotes Ara-
E16 1037-1041 Lives_In denotes Ara+
E17 1037-1041 Lives_In denotes Ara+
E18 1037-1041 Lives_In denotes Ara+
E19 1037-1041 Lives_In denotes Ara+
E20 1037-1041 Lives_In denotes Ara+
E21 1314-1318 Lives_In denotes Ara-
E22 1323-1327 Lives_In denotes Ara+
E23 1551-1566 Exhibits denotes B. pseudomallei
E24 1551-1566 Exhibits denotes B. pseudomallei
R7 E4 T11 Microorganism B. pseudomallei,B. pseudomallei
R8 E4 T12 Location B. pseudomallei,sera from patients with different clinical spectra and with other infections
R9 E5 T11 Microorganism B. pseudomallei,B. pseudomallei
R10 E5 T13 Location B. pseudomallei,patients with different clinical spectra and with other infections
R11 E6 T15 Microorganism Ara-,Ara-
R12 E6 T21 Location Ara-,sera from patients with melioidosis
R13 E7 T15 Microorganism Ara-,Ara-
R14 E7 T23 Location Ara-,hyperimmune mouse
R15 E8 T15 Microorganism Ara-,Ara-
R16 E8 T16 Location Ara-,clinical
R17 E9 T15 Microorganism Ara-,Ara-
R18 E9 T24 Location Ara-,hyperimmune mouse sera
R19 E10 T15 Microorganism Ara-,Ara-
R20 E10 T22 Location Ara-,patients with melioidosis
R21 E11 T17 Microorganism Ara-,Ara-
R22 E11 T24 Location Ara-,hyperimmune mouse sera
R23 E12 T17 Microorganism Ara-,Ara-
R24 E12 T23 Location Ara-,hyperimmune mouse
R25 E13 T17 Microorganism Ara-,Ara-
R26 E13 T21 Location Ara-,sera from patients with melioidosis
R27 E14 T17 Microorganism Ara-,Ara-
R28 E14 T22 Location Ara-,patients with melioidosis
R29 E15 T17 Microorganism Ara-,Ara-
R30 E15 T18 Location Ara-,soil
R31 E16 T19 Microorganism Ara+,Ara+
R32 E16 T24 Location Ara+,hyperimmune mouse sera
R33 E17 T19 Microorganism Ara+,Ara+
R34 E17 T21 Location Ara+,sera from patients with melioidosis
R35 E18 T19 Microorganism Ara+,Ara+
R36 E18 T20 Location Ara+,soil
R37 E19 T19 Microorganism Ara+,Ara+
R38 E19 T22 Location Ara+,patients with melioidosis
R39 E20 T19 Microorganism Ara+,Ara+
R40 E20 T23 Location Ara+,hyperimmune mouse
R41 E21 T25 Microorganism Ara-,Ara-
R42 E21 T27 Location Ara-,microtiter plates
R43 E22 T26 Microorganism Ara+,Ara+
R44 E22 T27 Location Ara+,microtiter plates
R45 E23 T31 Microorganism B. pseudomallei,B. pseudomallei
R46 E23 T30 Property B. pseudomallei,pathogenicity
R47 E24 T31 Microorganism B. pseudomallei,B. pseudomallei
R48 E24 T29 Property B. pseudomallei,virulence